Chevallard Daniel R.'s Form 4 filing
Viracta Therapeutics, Inc. (VIRX) · filed Feb 28, 2023
- Accession no.
- 0001209191-23-013854
- Filed
- Feb 28, 2023
- Trade date
- Feb 25-27, 2023
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.05K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Chevallard Daniel R.CIK 0001706176 | Officer (CFO and COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 25, 2023 | Common Stock | MOption exerciseAcquired | +6,889 | $0.00 | $0 | 92,622 | Direct | |
| Feb 27, 2023 | Common Stock | SSaleDisposed | −3,599 | $1.68 | −$6,046.32 | 89,023 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 25, 2023 | Common Stock | MOption exerciseDisposed | −6,889 | $0.00 | $0 | 61,999 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.